Prominent Runners: Benitec Biopharma Limited (NASDAQ:BNTC), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Benitec Biopharma Limited (NASDAQ:BNTC)

Benitec Biopharma Limited (NASDAQ:BNTC) belongs to Medical sector that surged 134.37% in value when last trading session closed at $3.75. The company has a market capitalization of $549.48 Million. The company’s stock has a Return on Assets (ROA) of 0 percent, a Return on Equity (ROE) of 0 percent and Return on Investment (ROI) of 0 percent. The company reached its 52-Week high of $4.44 on Feb 2, 2017 and 52-Week low of $1.2 on Jul 6, 2016.

Earnings per share (ttm) for Benitec Biopharma Limited (NASDAQ:BNTC) according to Finviz Data is $-1.56.

This company was Downgrade by Maxim Group on 26-Feb-16  to Hold.

The 1 analysts offering 12-month price forecasts for Benitec Biopharma Ltd have a median target of 5.19, with a high estimate of 5.19 and a low estimate of 5.19. The median estimate represents a +38.29% increase from the last price of 3.75.

Financial History:

The consensus recommendation for Benitec Biopharma Limited (NASDAQ:BNTC) is 3. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 3. In comparison, the consensus recommendation 60 days ago was at 3, and 90 days ago was at 3 respectively.

Company Profile:

Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA):

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belongs to Medical sector closed its last session with a loss of -0.02 percent and closed its previous trading session at $23.78. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $-0.18. The company has the Market capitalization of $4.62 Billion. The company’s stock has a Return on Assets (ROA) of -5.4 percent, a Return on Equity (ROE) of 37.1 percent and Return on Investment (ROI) of -62.9 percent. The company reached its 52-Week high of $23.85 on Jan 31, 2017 and 52-Week low of $4.37 on Feb 11, 2016.

This company was Downgrade by SunTrust on 11-Jan-17 to Hold.

The 8 analysts offering 12-month price forecasts for ARIAD Pharmaceuticals Inc have a median target of 24.00, with a high estimate of 24.00 and a low estimate of 14.00. The median estimate represents a +0.90% increase from the last price of 23.79.

Financial History:

Following Earnings result, share price were DOWN 15 times out of last 27 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 58% percent of times. It has met expectations  0 times and missed earnings  5  times.

The consensus recommendation for Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is 2.5. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2.33. In comparison, the consensus recommendation 60 days ago was at 2.33, and 90 days ago was at 2 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Ariad Pharmaceuticals Inc. to have earnings per share of $-0.18.

Revenue is expected to range from 42.5 Million to 47.57 Million with an average of 44.15 Million.

Company Profile:

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology.  The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology.  The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.